K. Haslam

发表

SYT-SSX is critical for cyclin D1 expression in synovial sarcoma cells: a gain of function of the t(X;18)(p11.2;q11.2) translocation.

G. Nilsson, Yuntao Xie, O. Larsson, 2002, Cancer research.

Mutation Status in Myeloid Malignancies Informs Clinical Insight

K. Haslam, 2019 .

No prognostic impact of P2RY8‐CRLF2 fusion in intermediate cytogenetic risk childhood B‐cell acute lymphoblastic leukaemia

S. Langabeer, K. Haslam, A. O'marcaigh, 2013, British journal of haematology.

Screening for CRLF2 overexpression in adult acute lymphoblastic leukemia

S. Langabeer, K. Haslam, J. Kelly, 2011, International journal of laboratory hematology.

Molecular heterogeneity of familial myeloproliferative neoplasms revealed by analysis of the commonly acquired JAK2, CALR and MPL mutations

S. Langabeer, K. Haslam, A. Hayat, 2014, Familial Cancer.

Assessment of CALR mutations in myelofibrosis patients, post‐allogeneic stem cell transplantation

S. Langabeer, M. McMullin, K. Haslam, 2014, British journal of haematology.

False-negative CALR mutation in a suspected myeloproliferative neoplasm: identification, resolution and corrective action

S. Langabeer, K. Haslam, H. Enright, 2018, Journal of Clinical Pathology.

Showing one’s true CALRs: spleen size and platelet count help refine the molecular diagnostic pathway for patients with splanchnic vein thrombosis

S. Langabeer, K. Haslam, 2017 .

A novel molecular assay using hybridisation probes and melt curve analysis for CALR exon 9 mutation detection in myeloproliferative neoplasms

Terry J. Smith, T. Keaney, K. Haslam, 2017, Journal of Clinical Pathology.

Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging Approaches

S. Langabeer, K. Haslam, 2016, BioMed research international.

CALR mutation profile in Irish patients with myeloproliferative neoplasms.

S. Langabeer, K. Haslam, M. Cahill, 2016, Hematology/oncology and stem cell therapy.

Incidence of CALR mutations in patients with splanchnic vein thrombosis

S. Langabeer, K. Haslam, 2015, British journal of haematology.

Distinct driver mutation profiles of childhood and adolescent essential thrombocythemia

S. Langabeer, K. Haslam, C. Mcmahon, 2015, Pediatric blood & cancer.

Monitoring Residual Disease in the Ph-Negative Myeloproliferative Neoplasms Post-Allogeneic Stem Cell Transplantation: More Mutations and More Methodologies

S. Langabeer, K. Haslam, E. Conneally, 2014, Front. Oncol..

The molecular landscape of childhood myeloproliferative neoplasms.

S. Langabeer, K. Haslam, C. Mcmahon, 2014, Leukemia research.

Cloning and characterization of spliced fusion transcript variants of synovial sarcoma: SYT/SSX4, SYT/SSX4v, and SYT/SSX2v. Possible regulatory role of the fusion gene product in wild type SYT expression.

O. Larsson, M. Starborg, A. Bartolazzi, 2001, Gene.

Chronic Myeloid Leukemia with an e6a2 BCR-ABL1 Fusion Transcript: Cooperating Mutations at Blast Crisis and Molecular Monitoring

S. Langabeer, K. Haslam, E. Conneally, 2017, Case reports in hematology.

Characterization of a novel variant BCR-ABL1 fusion transcript in a patient with chronic myeloid leukemia: Implications for molecular monitoring.

S. Langabeer, K. Haslam, E. Conneally, 2017, Hematology/oncology and stem cell therapy.

Molecular response to imatinib in chronic myeloid leukaemia with a variant e13a3 BCR–ABL1 fusion

S. Langabeer, K. Haslam, S. McCarron, 2015, Medical Oncology.

A novel, variant BCR‐ABL1 transcript not detected by standard real‐time quantitative PCR in a patient with chronic myeloid leukaemia

S. Langabeer, K. Haslam, S. McCarron, 2012, International journal of laboratory hematology.

V S R R H E H L V V A H G K G F A K A GTC AGT CGT CGT CAC GAG CAC CTG GTA GTG GCC CAT GGA AAA GGG TTT GCA AAA GCC

S. Langabeer, K. Haslam, S. McCarron, 2012 .

Acute Lymphoblastic Leukaemia with an e1a3 BCR-ABL1 Fusion

S. Langabeer, K. Haslam, J. Kelly, 2011, Acta Haematologica.

Sustained clinical remission despite suboptimal molecular response to imatinib in e1a2 BCR-ABL chronic myeloid leukemia.

S. Langabeer, K. Haslam, M. Cahill, 2010, Leukemia research.

Protracted Clonal Trajectory of a JAK2 V617F-Positive Myeloproliferative Neoplasm Developing during Long-Term Remission from Acute Myeloid Leukemia

S. Langabeer, K. Haslam, J. Quinn, 2018, Case reports in hematology.

Transient JAK2 V617F mutation in an aplastic anaemia patient with a paroxysmal nocturnal haemoglobinuria clone

S. Langabeer, K. Haslam, H. Enright, 2013, British journal of haematology.

Targeted next‐generation sequencing of familial platelet disorder with predisposition to acute myeloid leukaemia

S. Langabeer, K. Haslam, A. Hayat, 2016, British journal of haematology.

Evading Capture by Residual Disease Monitoring: Extramedullary Manifestation of JAK2 V617F-Positive Primary Myelofibrosis After Allogeneic Stem Cell Transplantation

S. Langabeer, K. Haslam, R. Flavin, 2015, Case reports in hematology.

The incidence of co-existing BCR-ABL1 and JAK2 V617F rearrangements: implications for molecular diagnostics.

S. Langabeer, K. Haslam, S. McCarron, 2012, Laboratory hematology : official publication of the International Society for Laboratory Hematology.

Allogeneic Hematopoietic Stem Cell Transplantation for a BCR-FGFR1 Myeloproliferative Neoplasm Presenting as Acute Lymphoblastic Leukemia

S. Langabeer, K. Haslam, N. O'Connell, 2012, Case reports in hematology.

Molecular heterogeneity of familial myeloproliferative neoplasms revealed by analysis of the commonly acquired JAK2, CALR and MPL mutations

S. Langabeer, K. Haslam, A. Hayat, 2014, Familial Cancer.

International external quality assurance of JAK2 V617F quantification

Niels Pallisgaard, Beatriz Bellosillo, Dina Naguib, 2018, Annals of Hematology.

Suboptimal molecular response to tyrosine kinase inhibition associated with acquisition of a T240A ABL1 kinase domain mutation in a patient with chronic myeloid leukemia.

S. Langabeer, K. Haslam, M. Crampe, 2019, Experimental oncology.

A prenatal origin of childhood essential thrombocythaemia

S. Langabeer, K. Haslam, C. Mcmahon, 2013, British journal of haematology.

Prediction of disability-free survival in healthy older people

Michael S. Warren, H. C. Siew, Suzanne G. Orchard, 2022, GeroScience.

Molecular diagnostics of myeloproliferative neoplasms

S. Schnittger, S. Carillo, E. Lippert, 2015, European journal of haematology.

Who to screen for calreticulin mutations? An audit of real-life practice and review of current evidence.

S. Langabeer, K. Haslam, 2017, European journal of internal medicine.

Acute Lymphoblastic Leukemia Arising in CALR Mutated Essential Thrombocythemia

S. Langabeer, C. Ryan, K. Haslam, 2016, Case reports in hematology.

Neutrophilia and the JAK2 V617F Mutation

S. Langabeer, K. Haslam, 2017, Pathology & Oncology Research.

Targeted next-generation sequencing identifies clinically relevant mutations in patients with chronic neutrophilic leukemia at diagnosis and blast crisis

S. Langabeer, K. Haslam, J. Quinn, 2018, Clinical and Translational Oncology.

Evaluation of a JAK2 V617F quantitative PCR to monitor residual disease post-allogeneic hematopoietic stem cell transplantation for myeloproliferative neoplasms

S. Langabeer, K. Haslam, K. Molloy, 2013, Clinical chemistry and laboratory medicine.

Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms.

S. Langabeer, K. Haslam, M. Percy, 2018, Genetic testing and molecular biomarkers.

Inter-Laboratory Evaluation of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia

K. Mills, S. Langabeer, K. Haslam, 2016, Molecular Diagnosis & Therapy.

An acquired NRAS mutation contributes to neutrophilic progression in a patient with primary myelofibrosis

S. Langabeer, K. Haslam, E. Conneally, 2018, British journal of haematology.

CALR mutations are rare in childhood essential thrombocythemia

S. Langabeer, K. Haslam, C. Mcmahon, 2014, Pediatric blood & cancer.

Incidence and significance of FLT3-ITD and NPM1 mutations in patients with normal karyotype acute myeloid leukaemia

S. Langabeer, K. Haslam, S. Langabeer, 2010, Irish journal of medical science.

Lack of myeloproliferative neoplasm-associated CALR mutations in acute promyelocytic leukemia

S. Langabeer, K. Haslam, 2015, Leukemia & lymphoma.

The mutant CALR allele burden in essential thrombocythemia at transformation to acute myeloid leukemia.

S. Langabeer, K. Haslam, E. Elhassadi, 2017, Blood Cells, Molecules & Diseases.

Considerations and recommendations for a new molecular diagnostic algorithm for the myeloproliferative neoplasms.

S. Langabeer, K. Haslam, 2014, Genetic testing and molecular biomarkers.

Assessment of CALR mutations in myelofibrosis patients, post‐allogeneic stem cell transplantation

S. Langabeer, M. McMullin, K. Haslam, 2014, British journal of haematology.

The JAK2 V617F Allele Burden in Latent Myeloproliferative Neoplasms Presenting with Splanchnic Vein Thrombosis

S. Langabeer, K. Haslam, K. Murphy, 2015, Pathology & Oncology Research.